Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001801917Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE TESTSubmission Contact InformationIs this a Live of the second secon

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

001-40782 7th Floor 50 Broadway London UNITED KINGDOM SW1H 0DB 44 207 400 3347 Eric Venker

Roivant Sciences Ltd.

President & CEO

144: Securities Information

| Title of the Class of Securities To Be Sold | Name and Address of the Broker | Number of Shares or Other Units To Be Sold | Aggregate Market Value | Number of Shares or Other Units Outstanding | Approximate Date of Sale | Name the Securities Exchange |
|--|--|---|------------------------------|--|-----------------------------|------------------------------------|
| Common shares, \$0.0000000341740141 par value per share ("Common Shares") | E*TRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005 | 28937 | 322068.81 | 766811433 | 07/21/2023 | Nasdaq |

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

| Title of the Class | Date you Acquired | Nature of Acquisition Transaction | Name of Person from Whom Acquired | Is this a Gift? | Date Donor Acquired | Amount of Securities Acquired | Date of Payment | Nature of Payment * |
|-----------------------|----------------------|---|--|--------------------------|---------------------------|-------------------------------------|--------------------|------------------------|
| Common Shares | 07/20/2023 | Restricted Stock Units granted under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan | Roivant Sciences Ltd. | | | 28937 | 07/20/2023 N/ | 'A |

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

| Name and Address of Seller | Title of Securities Sold | Date of Sale | Amount of Securities Sold | Gross Proceeds |
|--|--------------------------|-----------------|---------------------------------|----------------|
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 04/26/2023 | 72906 | 631675.25 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 04/27/2023 | 73514 | 625908.88 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 04/28/2023 | 75823 | 641877.24 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 05/01/2023 | 61155 | 525251.75 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 05/02/2023 | 109074 | 897477.32 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 05/03/2023 | 118760 | 997196.4 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 05/04/2023 | 88838 | 737504.16 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 05/08/2023 | 61206 | 546237.33 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 05/09/2023 | 238724 | 2203422.52 |

| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 05/23/2023 15671 | 150128.18 |
|--|---------------|-------------------|------------|
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 05/23/2023 415 | 4087.75 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 06/07/2023 201 | 1979.85 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 06/09/2023 299384 | 2966895.44 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 06/22/2023 15882 | 158978.82 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common Shares | 07/20/2023 159387 | 1802034.65 |

144: Remarks and Signature

RemarksThe securities included in Table I represent a maximum number of shares that may be sold to cover the
reporting person's tax obligations when restricted stock units belonging to the reporting person are settled.
The securities reported in Table I do not represent discretionary trades by the reporting person, and will be
sold, or were sold, as applicable, for the limited purpose of satisfying tax withholding obligations. Table II
does not include shares that were "net settled" by the Issuer in order to satisfy applicable tax withholding
obligations in connection with the vesting and settlement of Restricted Stock Units previously granted to
the reporting person.Date of Notice07/21/2023Date of Plan
Adoption or Giving
of Instruction, If02/17/2022

of Instruction, If 02/17 Relying on Rule 10b5-1 *ATTENTION:*

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Eric Venker

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)